TIDMAGL
RNS Number : 1486V
Angle PLC
26 January 2017
For immediate release 26 January 2017
ANGLE plc ("the Company")
POSITIVE INTERIM EVALUATION OF OVARIAN CANCER CLINICAL
STUDIES
Patient enrolment European study now over 90% complete and US
study 70% complete
Headline data from the full studies expected in Q2, 2017
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company,
is delighted to announce the outcome from the planned interim
evaluations of two separate 200 patient ovarian cancer studies, in
Europe and the United States.
The early evaluation of data from both the studies suggest that
an assay using the Parsortix system could accurately differentiate
between women with a malignant pelvic mass and those with benign
tumours, with an additional benefit of providing valuable gene
expression information which could help further refine treatment
decisions. Such data, if confirmed over the remaining samples,
would represent an advantage over currently available clinical risk
assessment tools.
The European study is being led by Dr Robert Zeillinger at the
Medical University of Vienna and the US study is being led by Dr
Richard Moore at the University of Rochester Medical Center, Wilmot
Cancer Institute (New York State). An evaluation of data obtained
from the first 50 patients enrolled in each study was undertaken,
at the interim stage, in order to optimise the combination of RNA
markers to detect malignancy.
The women in both studies had blood drawn prior to surgery for a
diagnosed pelvic mass. The blood was processed through the
Parsortix system to harvest, for evaluation, any circulating tumour
cells (CTCs) that may have been present. The early evaluation of
the data indicates that an RNA analysis of those cells harvested by
the Parsortix system may enable the accurate and specific diagnosis
of ovarian cancer in women with a pelvic mass.
Patient enrolment into the European study is now over 90% and is
expected to be completed in February 2017. The US study patient
enrolment is ahead of schedule with approximately 70% of the
required patient sample enrolled and currently on target to be
completed by the end of April 2017. Headline data from the full
studies is expected to be available in Q2, 2017.
Ovarian cancer surgery is highly complex and informed decision
making has a very strong impact on survival: women with a diagnosis
or a strong indication of ovarian cancer are normally referred to a
specialist gynaecologic oncology unit for surgery, while others
will fall under the care of a local general surgeon or
gynaecologist. Both clinical outcomes and costs are significantly
impacted by having the right surgical team in place for the right
procedure. It would therefore be of significant clinical benefit to
know, in advance of surgery, whether an abnormal pelvic mass is
malignant or benign. ANGLE estimates that the addressable global
market for the pre-surgical assessment of ovarian cancer risk,
could be in excess of GBP300 million per annum.
Professor Robert Zeillinger, Head of the Molecular Oncology
Group at the Medical University of Vienna, commented:
"The early data evaluation is encouraging. Using ANGLE's
Parsortix system and a panel of RNA markers, there is the prospect
we can meet a key medical need in triaging women before surgery to
ensure patients with cancer get the care they need."
Dr Richard Moore, Director of the Gynecologic Oncology Division,
University of Rochester Medical Center Wilmot Cancer Institute,
commented:
"The early data points are very promising and indicate that use
of a multiplex RNA assay on harvested circulating tumour cells will
help to accurately discriminate malignant from benign pelvic masses
before surgery and at the same time provide valuable tumour
specific genomic information that can help manage patients and
their disease in a way that is not currently possible."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"The interim data evaluation supports the potential for ANGLE's
first clinical application to out-perform standard of care for the
detection of ovarian cancer, particularly in relation to
specificity avoiding false positives. Additionally there is an
opportunity using Parsortix to obtain molecular information to
guide therapy prior to surgery, which is not possible with existing
approaches."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser),
Steve Cox
Russell Kerr (Sales) 020 7397 8900
WG Partners
David Wilson
Claes Spång 020 3705 9330
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberly Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China, Japan
and Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESUVUARBKAAUUR
(END) Dow Jones Newswires
January 26, 2017 02:01 ET (07:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024